The Zelnorm Epidemiologic Study (ZEST): A Cohort Study Evaluating Incidence of Abdominal and Pelvic Surgery Related to Tegaserod Treatment

DSpace/Manakin Repository

The Zelnorm Epidemiologic Study (ZEST): A Cohort Study Evaluating Incidence of Abdominal and Pelvic Surgery Related to Tegaserod Treatment

Citable link to this page

 

 
Title: The Zelnorm Epidemiologic Study (ZEST): A Cohort Study Evaluating Incidence of Abdominal and Pelvic Surgery Related to Tegaserod Treatment
Author: Quinn, Sherry; Earnest, David L; Rivero, Elena; Seeger, John; Lembo, Anthony J.; Kuo, Braden; Walker, Alexander M.

Note: Order does not necessarily reflect citation order of authors.

Citation: Seeger, John, Sherry Quinn, David L. Earnest, Anthony J. Lembo, Braden Kuo, Elena Rivero, and Alexander M. Walker. 2012. The Zelnorm epidemiologic study (ZEST): A cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterology 12:171.
Full Text & Related Files:
Abstract: Background: Pre-marketing clinical studies of tegaserod suggested an increased risk of abdominal surgery, particularly cholecystectomy. We sought to quantify the association between tegaserod use and the occurrence of abdominal or pelvic surgery, including cholecystectomy. Methods: This cohort study was conducted within an insured population. Tegaserod initiators and similar persons who did not initiate tegaserod were followed for up to six months for the occurrence of abdominal or pelvic surgery. Surgical procedures were identified from health insurance claims validated by review of medical records. The incidence of confirmed outcomes was compared using both as-matched and as-treated analyses. Results: Among 2,762 tegaserod initiators, there were 94 abdominal or pelvic surgeries (36 gallbladder): among 2,762 comparators there were 134 abdominal or pelvic surgeries (37 gallbladder) (hazard ratio HR] = 0.70, 95% confidence interval [C.I.] = 0.54-0.91 overall, HR = 0.98, 95% C.I. = 0.62-1.55 for gallbladder). Current tegaserod exposure compared to nonexposure was associated with a rate ratio [RR] of 0.68 (95% C.I. = 0.48-0.95) overall, while the RR was 0.99 (95% C.I. = 0.56-1.77) for gallbladder surgery. Conclusions: In this study, tegaserod use was not found to increase the risk of abdominal or pelvic surgery nor the specific subset of gallbladder surgery.
Published Version: doi:10.1186/1471-230X-12-171
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536557/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10609765
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters